Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...113114115116117118119120121122123...401402»
  • ||||||||||  Review, Journal:  Accounting Gut Microbiota as the Mediator of Beneficial Effects of Dietary (Poly)phenols on Skeletal Muscle in Aging. (Pubmed Central) -  May 31, 2023   
    In older individuals, the gut microbiota is frequently characterized by dysbiosis, overrepresentation of opportunistic pathogens, and increased inter-individual variability, which may contribute to increasing the variability of biological actions of phenolic compounds at the skeletal muscle level. These interactions should be taken into great consideration for designing effective nutritional strategies to counteract sarcopenia.
  • ||||||||||  ursodeoxycholic acid / Generic mfg.
    Journal:  Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux. (Pubmed Central) -  May 31, 2023   
    This suggests that BCAA may represent a useful prognostic marker in the staging of liver disease severity. Our results indicate that UDCA induces sarcopenia in mice and sarcopenic-like features in CC myotubes and/or isolated muscle fibers concomitantly with decreased protein synthesis and alterations in autophagic flux.
  • ||||||||||  Journal:  COVID-19 and sarcopenia-related traits: a bidirectional Mendelian randomization study. (Pubmed Central) -  May 30, 2023   
    Our study first explored the causal relationship between COVID-19 and SP-related traits, but the result indicated that they may indirectly interact with each other. We highlighted that older people had better absorb enough nutrition and strengthen exercise to directly cope with SP during the COVID-19 pandemic.
  • ||||||||||  Lusefi (luseogliflozin) / Taisho
    Preclinical, Journal:  Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats. (Pubmed Central) -  May 30, 2023   
    Muscle atrophy in streptozotocin-induced hyperglycemic model rats was inhibited by the suppression of hyperglycemia using luseogliflozin, which consequently suppressed hyperglycemia-mediated increase in the levels of advanced glycation end products (AGEs) and activated the protein degradation pathway in muscle cells. Treatment with luseogliflozin can restore the hyperglycemia-induced loss in the muscle mass to some degree partly through the inhibition of AGEs-induced or homeostatic disruption of mitochondria-induced activation of muscle degradation.
  • ||||||||||  Journal:  Can artificial intelligence simplify the screening of muscle mass loss? (Pubmed Central) -  May 30, 2023   
    The new results might suggest a possible inversion of the standard diagnostic algorithm of sarcopenia. We conjecture a new diagnostic scheme, which requires a dedicated clinical validation that goes beyond the scope of the present study.
  • ||||||||||  Journal:  Combining sarcopenia and ASA status to inform emergency laparotomy outcomes: could it be that simple? (Pubmed Central) -  May 30, 2023   
    These findings reinforce that HGS may be a simple and inexpensive method to identify early signs of cognitive decline and that studies and rehabilitation strategies should be more sex specific. Combining the semi-physiological parameter ASA classification with PM:L3 provides a quick and simple alternative to the more complex established risk assessment scores and is superior to PM:L3 alone.
  • ||||||||||  Trial completion date, Trial primary completion date:  INERTIA: The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia (clinicaltrials.gov) -  May 30, 2023   
    P=N/A,  N=90, Recruiting, 
    Combining the semi-physiological parameter ASA classification with PM:L3 provides a quick and simple alternative to the more complex established risk assessment scores and is superior to PM:L3 alone. Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
  • ||||||||||  Review, Journal:  Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease. (Pubmed Central) -  May 27, 2023   
    We present herein a precision medicine approach for FLD based on our recently proposed subcategorization, which includes the metabolic-associated FLD (MAFLD) (i.e., obesity-associated FLD (OAFLD), sarcopenia-associated FLD (SAFLD, and lipodystrophy-associated FLD (LAFLD)), genetics-associated FLD (GAFLD), FLD of multiple/unknown causes (XAFLD), and combined causes of FLD (CAFLD) as well as advanced stage fibrotic FLD (FAFLD) and end-stage FLD (ESFLD) subcategories. These and other related advances, as a whole, are expected to enable not only improved patient care, quality of life, and long-term disease outcomes, but also a considerable reduction in healthcare system costs associated with FLD, along with more options for better-targeted, more effective treatments in the near future.
  • ||||||||||  Biomarker, Journal:  Sarcopenia Is a Prognostic Factor in Patients Undergoing Percutaneous Endoscopic Gastrostomy. (Pubmed Central) -  May 27, 2023   
    Propensity score-matched analysis (n = 37 vs. 37) showed that the survival rate was lower in the sarcopenia group than in the non-sarcopenia group (at 90 days: 77% (95% CI, 59-88) vs. 92% (76-97), at 180 days: 56% (38-71) vs. 92% (76-97), and at one year: 35% (19-51) vs. 81% (63-91), p = 0.0014). (4) Sarcopenia was associated with poor prognosis in patients having undergone PEG.
  • ||||||||||  Observational data, Journal:  The High Prevalence of Sarcopenia in Rheumatoid Arthritis in the Korean Population: A Nationwide Cross-Sectional Study. (Pubmed Central) -  May 27, 2023   
    In subgroup analysis which was stratified by age (age under 40, age between 40 and 59, age over 60), the OR for sarcopenia was higher in men with age over 60 years (OR, 4.12; 95% CI, 1.48-11.44) and women with age between 40 and 59 (OR, 2.29; 95% CI, 1.05-5.00). The prevalence of sarcopenia was higher in Korean men with RA and women with RA in middle age, suggesting the management of muscle loss will be needed, especially in Koreans with RA.
  • ||||||||||  Journal:  Whole Blood Spermine/Spermidine Ratio as a New Indicator of Sarcopenia Status in Older Adults. (Pubmed Central) -  May 27, 2023   
    Additionally, when the odds ratio was analyzed with spermine/spermidine instead of polyamine concentrations, only for spermine/spermidine, the odds ratio values varied in parallel with the progression of sarcopenia. Based on the present data, we believe that the blood spermine/spermidine ratio may be a diagnostic indicator of risk for sarcopenia.
  • ||||||||||  Review, Journal:  Osteosarcopenia and Pain: Do We Have a Way Out? (Pubmed Central) -  May 27, 2023   
    Based on this evidence, we conducted a narrative review using the PubMed and Google Scholar search engines to summarize the current knowledge on the molecular mechanisms involved in the pain development in OSP and the potential countermeasures to be taken. The lack of studies addressing this topic highlights the need to conduct new research into the resolution of an ever-expanding social problem.
  • ||||||||||  Review, Journal:  Microalgae Produce Antioxidant Molecules with Potential Preventive Effects on Mitochondrial Functions and Skeletal Muscular Oxidative Stress. (Pubmed Central) -  May 27, 2023   
    Under conditions of traumatic exercise or muscular diseases, a high production of reactive oxygen species (ROS) at the origin of oxidative stress (OS) will lead to inflammation and muscle atrophy, with life-long consequences. In this review, we describe the potential antioxidant effects of microalgae and their biomolecules on mitochondrial functions and skeletal muscular oxidative stress during exercises or in musculoskeletal diseases, as in sarcopenia, chronic obstructive pulmonary disease (COPD) and Duchenne muscular dystrophy (DMD), through the increase in and regulation of antioxidant pathways and protein synthesis.
  • ||||||||||  Journal:  Reply to zhou et al. (Pubmed Central) -  May 25, 2023   
    No abstract available No abstract available